SAN FRANCISCO, Aug. 21, 2017 -- Posit Science, the maker of BrainHQ online brain training exercises and assessments, and MPI Cognition, the organization disseminating the Bredesen Protocol for treating cognitive decline and those at risk for cognitive decline, announced today that BrainHQ will be made available to every patient enrolled in the Bredesen Protocol.
Dr. Dale Bredesen, co-founder of MPI Cognition, is an internationally-recognized expert in aging and neurodegenerative diseases. He earned his MD at Duke University, served as Chief Resident in Neurology at University of California, San Francisco (UCSF), was an NIH Postdoctoral Fellow in Nobel laureate Stanley Prusiner’s lab at UCSF, held faculty positions at UCSF, UCSD and UCLA, and was the founding President and CEO of the Buck Institute for Research on Aging. He has authored the book The End of Alzheimer’s: The First Program to Prevent and Reverse Cognitive Decline, due for publication this week.
In 2014 and 2016, Dr. Bredesen documented what are believed to be the first cases showing some reversal of the symptoms of Alzheimer’s, using a novel, personalized programmatic approach that addresses the underlying contributors to cognitive decline in Alzheimer’s disease. Ten patients with cognitive decline (Mild Cognitive Impairment, Subjective Cognitive Impairment, and early Alzheimer’s), were put on this protocol and followed – with nine showing improvements. Further refinements led to the Bredesen Protocol and a subsequent article reporting imaging results showing structural changes to the brains of treated patients.
The Bredesen Protocol has been taught to hundreds of physicians – first, by Dr. Bredesen, and, now, by the Institute for Functional Medicine. Its effects are being monitored and studied in many places, included a trial at the Cleveland Clinic.
The Bredesen Protocol helps physicians identify the issues contributing to cognitive decline and Alzheimer’s in each patient and, then, address those specific issues with a personalized treatment plan. Typically, treatments include monitoring and taking steps to adjust diet, exposure to inflammatory agents and toxins, physical exercise, sleep, and stress, as well as having patients engage in brain exercises.
“At first, we tried a lot of different brain training programs,” said Dr. Bredesen, “but we found that BrainHQ has the most validated science, and like the rest of our protocol, it personalizes to each patient and his or her needs. We made a decision last year to get all the patients access to BrainHQ, and we have now implemented that decision.”
“There’s an emerging consensus that we will need to treat neurodegenerative disorders with a multi-factorial approach tailored to the individual, rather than a silver bullet,” said Dr. Henry Mahncke, CEO of Posit Science. “We are honored to be working with Bredesen Protocol practitioners and with research study investigators on this important medical frontier.”
More than 140 peer-reviewed papers have shown that the exercises and assessments in BrainHQ deliver a wide range of benefits in varied populations, including improvements in healthy older adults in standard measures of cognition (e.g., speed, attention, memory and executive function), which have been shown to generalize to quality of life (e.g., mood, confidence, functional independence, self-rated health) and to real world activities (e.g., gait, balance, driving and everyday cognition).
BrainHQ exercises and assessments also have been, and continue to be, used in scores of research studies of clinical populations, as a predicate to seeking regulatory approvals, where usage is deemed successful.
For more information, contact [email protected].


Robinhood Expands Sports Event Contracts With Player Performance Wagers
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 



